Ubrogepant in the Acute Management of Migraine: A Narrative Review.
Chia-Chun ChiangJuliana H VanderPluymPublished in: Journal of pain research (2021)
Ubrogepant is a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist that received Food and Drug Administration (FDA) approval for the acute treatment of migraine with and without aura in adults. The ACHIEVE I and ACHIEVE II Phase III clinical trials showed that ubrogepant was superior to placebo for pain freedom and freedom of the most bothersome migraine-associated symptom at 2 hours after medication intake. The 52-week open label extension of the Phase III trials demonstrated safety of ubrogepant. A real-world study conducted at a tertiary headache center also confirmed the efficacy and safety of ubrogepant. Adverse event rates were higher in the real-world population. Studies are needed to evaluate its long-term efficacy and safety, especially in the setting of co-administration with other CGRP modulating therapies such as the CGRP monoclonal antibodies.
Keyphrases
- phase iii
- open label
- clinical trial
- drug administration
- small molecule
- phase ii
- liver failure
- placebo controlled
- double blind
- respiratory failure
- drug induced
- phase ii study
- chronic pain
- study protocol
- aortic dissection
- healthcare
- pain management
- squamous cell carcinoma
- randomized controlled trial
- hepatitis b virus
- spinal cord injury
- genome wide
- gene expression
- adverse drug
- copy number
- human health
- acute respiratory distress syndrome
- protein protein